Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
Read the full story at MarketWatch.com - Top Stories →
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
Read the full story at MarketWatch.com - Top Stories →
€
€
€
€